These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 29856361

  • 1. Lymphomatoid Granulomatosis with Isolated Cutaneous Lesions: Prolonged Remission After DA-EPOCH Protocol.
    Gupta VG, Gogia A, Sharma V, Mallick S.
    Turk J Haematol; 2018 Aug 03; 35(3):213-214. PubMed ID: 29856361
    [No Abstract] [Full Text] [Related]

  • 2. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial.
    Melani C, Dowdell K, Pittaluga S, Dunleavy K, Roschewski M, Song JY, Calattini S, Kawada JI, Price DA, Chattopadhyay PK, Roederer M, Lucas AN, Steinberg SM, Jaffe ES, Cohen JI, Wilson WH.
    Lancet Haematol; 2023 May 03; 10(5):e346-e358. PubMed ID: 37011643
    [Abstract] [Full Text] [Related]

  • 3. Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.
    Roswarski J, Roschewski M, Lucas A, Melani C, Pittaluga S, Jaffe ES, Steinberg SM, Waldmann TA, Wilson WH.
    Leuk Lymphoma; 2018 Jun 03; 59(6):1466-1469. PubMed ID: 29032710
    [No Abstract] [Full Text] [Related]

  • 4. Lymphomatoid granulomatosis. Successful treatment with CHOP combination chemotherapy.
    Drasga RE, Williams SD, Wills ER, Roth LM, Einhorn LH.
    Am J Clin Oncol; 1984 Feb 03; 7(1):75-80. PubMed ID: 6546471
    [Abstract] [Full Text] [Related]

  • 5. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
    Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA.
    Br J Haematol; 2017 Nov 03; 179(3):503-506. PubMed ID: 27378601
    [No Abstract] [Full Text] [Related]

  • 6. Syndrome of inappropriate antidiuretic hormone secretion associated with primary cutaneous anaplastic large cell lymphoma.
    Hirata Y, Yokote T, Nishiwaki U, Tsuji M, Hanafusa T.
    Br J Haematol; 2012 May 03; 157(4):412. PubMed ID: 22409317
    [No Abstract] [Full Text] [Related]

  • 7. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S, Batlle A, de Villambrosia SG, Carnicero F, Ferrando-Lamana L, Piris MA, Lopez A.
    Br J Haematol; 2015 Apr 03; 169(2):188-98. PubMed ID: 25521006
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ, Jiang WQ, Wang W, Zhou ZM, Xia ZJ, Lin XB, Li YH, Xu RH, Zhang L, Xu GC, Sun XF, Liu DG, He YJ, Guan ZZ.
    Ai Zheng; 2003 Apr 03; 22(4):389-92. PubMed ID: 12703995
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lymphomatoid granulomatosis: a case report with unique clinical and histopathologic features.
    Boone JM, Zhang D, Fan F.
    Ann Clin Lab Sci; 2013 Apr 03; 43(2):181-5. PubMed ID: 23694794
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas.
    Roswarski J, Roschewski M, Melani C, Pittaluga S, Lucas A, Steinberg SM, Jaffe ES, Waldmann TA, Wilson WH.
    Leuk Lymphoma; 2019 Aug 03; 60(8):2062-2066. PubMed ID: 30626252
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.